SB-269970

SB-269970 is a potent, selective and brain-penetrant 5-HT7 receptor antagonist with a pKi of 8.3. SB-269970 exhibits >50-fold selectivity against other 5-HT receptors[1][2].

Product Specifications

CAS Number

[201038-74-6]

UNSPSC

12352005

Target

5-HT Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/SB-269970.html

Purity

98.78

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=CC=CC(S(=O)(N2[C@@H](CCN3CCC(C)CC3)CCC2)=O)=C1

Molecular Formula

C18H28N2O3S

Molecular Weight

352.49

References & Citations

[1]Hagan JJ, et al. Characterization of SB-269970-A, a selective 5-HT (7) receptor antagonist. Br J Pharmacol. 2000 Jun;130 (3) :539-48.|[2]Roberts C, et al. The effect of SB-269970, a 5-HT (7) receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. Br J Pharmacol. 2001 Apr;132 (7) :1574-80.|[3]Nikiforuk A, et al. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One. 2013 Jun 11;8 (6) :e66695.|[4]Monti JM, et al. The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat. Behav Brain Res. 2008 Aug 22;191 (2) :184-9.